Therapeutics News and Research

RSS

Emerging infectious diseases will continue to confront society in unpredictable ways as long as humans and microbes co-exist

Emerging infectious diseases, which have shaped the course of humanity and caused incalculable suffering and death, will continue to confront society in unpredictable ways as long as humans and microbes co-exist

9 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

A team of researchers led by The Burnham Institute’s Robert C. Liddington has determined the crystal structure of the binding complex between anthrax toxin and one of its host receptors.

8 Jul 2004

Children cured of acute lymphocytic leukemia after chemotherapy have a 5-20 times greater risk of developing secondary malignant neoplasm's

The alterations in the children's gene sequence remain embedded within their chromosomes and may pose elevated risk for development of second malignancies and other diseases later in life, cautioned Barry A. Finette, M.D., Ph.D., associate professor of pediatrics at the University of Vermont.

1 Jul 2004

The medical use of marijuana

The medical use of marijuana enjoys wide public support. More than 70% of respondents to recent surveys agree that marijuana should be available medically. Sources: Pew Research Center for the People & the Press conducted by Princeton Survey Research Associates. Feb. 14-19, 2001 and The Gallup Poll. March 19-21, 1999.

30 Jun 2004

Launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies

Mattel Children's Hospital at UCLA announced the launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies at UCLA June 28.

29 Jun 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Stimulation or drugs that target the pro-opiomelanocortin system will be effective in treating diabetes or obesity

There’s more than one way to slim a cat - at least that’s the hope of University of Florida obesity researchers, who believe pets and even people may someday benefit from gene therapy research aimed at breaking through the biochemical bottleneck that makes many middle-aged mammals gain weight.

17 Jun 2004

New Cincinnati adult diabetes center

The Diabetes Center at the University of Cincinnati is a joint effort by UC and community leaders to improve diabetes care in the region and open the door to more community programs addressing the health care needs of people with diabetes.

15 Jun 2004

Drug combination reduces cocaine use

Researchers at the Yerkes National Primate Research Center are the first to demonstrate that a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.

15 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

Real-Time Immuno-PCR has the ability to detect HIV infection earlier than all current methods

Researchers at the Institute of Human Virology have developed an ultra-sensitive testing technique that has shown the ability to detect HIV infection earlier than all current methods.

15 Jun 2004

University of Cambridge to generate antibodies

The University of Cambridge has announced a licensing agreement with Human-Human Hybridoma, Inc. (3H) to exploit a human myeloma cell line (Karpas-707H) that can be used in research and for the production of human monoclonal antibodies.

15 Jun 2004

Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics

Though there has been considerable biological and political debate over the use of embryonic stem cells (ESCs) vs. adult stem cells (ASCs) as therapies for tissue engineering and organ transplants, inherent benefits and drawbacks in both techniques compel them to coexist and complement each other.

10 Jun 2004

Project aimed at eliminating anthrax as a potential weapon for terrorists

La Trobe University scientists are using their own unique peptide 'library' containing a thousand million molecular sequences in a project aimed at eliminating anthrax as a potential weapon for terrorists.

10 Jun 2004

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

A biological agent — a drug that wraps vitamin A inside bubbles of fat — used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M. D. Anderson Cancer Center.

7 Jun 2004

200 new therapies are being developed for prostate cancer

The Prostate Cancer Foundation (PCF) has announced that more than 200 new therapies are being developed for prostate cancer, many by researchers supported by the PCF. Substantially more prostate cancer therapies are in later stages of clinical development (Phases II and III) than ever before.

5 Jun 2004

New medical patent covering the generation of genetically enhanced therapeutic antigens

Morphotek, Inc. announced today the issuance of United States Patent 6,737,268 covering the generation of genetically enhanced therapeutic antigens.

2 Jun 2004

36 percent of Americans are using complementary and alternative medicines

A new, comprehensive government survey, released by the National Center for Complementary and Alternative Medicine (NCCAM), reveals that 36 percent of Americans are incorporating complementary and alternative medicines (CAM) into their health care regimen.

1 Jun 2004

New company is developing advanced therapeutics for stroke victims

Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials.

26 May 2004

Therapeutics News and Research

Emerging infectious diseases will continue to confront society in unpredictable ways as long as humans and microbes co-exist

Natural products to be developed as anti-cancer therapeutics

New leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax

Children cured of acute lymphocytic leukemia after chemotherapy have a 5-20 times greater risk of developing secondary malignant neoplasm's

The medical use of marijuana

Launch of the Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies

Exelixis files new drug application for a proprietary novel anticancer compound

Stimulation or drugs that target the pro-opiomelanocortin system will be effective in treating diabetes or obesity

New Cincinnati adult diabetes center

Drug combination reduces cocaine use

SARS siRNA studied further to help many respiratory diseases including lung cancer

Real-Time Immuno-PCR has the ability to detect HIV infection earlier than all current methods

University of Cambridge to generate antibodies

Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics

Project aimed at eliminating anthrax as a potential weapon for terrorists

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

200 new therapies are being developed for prostate cancer

New medical patent covering the generation of genetically enhanced therapeutic antigens

36 percent of Americans are using complementary and alternative medicines

New company is developing advanced therapeutics for stroke victims

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News